![](/img/cover-not-exists.png)
A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
Genovese, M. C., Lee, E., Satterwhite, J., Veenhuizen, M., Disch, D., Berclaz, P.-Y., Myers, S., Sides, G., Benichou, O.Volume:
72
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2012-202864
Date:
September, 2013
File:
PDF, 565 KB
english, 2013